tiprankstipranks
Advertisement
Advertisement

VSTM Stock Latest News

Verastem price target lowered to $13 from $14 at Mizuho
The FlyVerastem price target lowered to $13 from $14 at Mizuho
14d ago
VSTM
Verastem price target lowered to $13 from $14 at Mizuho
PremiumThe Fly
Verastem price target lowered to $13 from $14 at Mizuho
15d ago
VSTM
Verastem Earnings Call Highlights Cash, Pipeline Momentum
PremiumCompany Announcements
Verastem Earnings Call Highlights Cash, Pipeline Momentum
17d ago
VSTM
Verastem Restructures Oberland Financing to Support Commercialization
PremiumCompany Announcements
Verastem Restructures Oberland Financing to Support Commercialization
18d ago
8K
VSTM
Verastem price target lowered to $12 from $14 at Guggenheim
PremiumThe Fly
Verastem price target lowered to $12 from $14 at Guggenheim
18d ago
VSTM
Verastem Reiterated as Buy on Strong AVMAPKI FAKZYNJA Momentum, VS-7375 Progress; $18 Price Target Maintained
PremiumRatingsVerastem Reiterated as Buy on Strong AVMAPKI FAKZYNJA Momentum, VS-7375 Progress; $18 Price Target Maintained
18d ago
VSTM
Verastem reports Q2 adjusted EPS (31c), consensus (44c)
Premium
The Fly
Verastem reports Q2 adjusted EPS (31c), consensus (44c)
19d ago
VSTM
Is VSTM a Buy, Before Earnings?
Premium
Pre-Earnings
Is VSTM a Buy, Before Earnings?
21d ago
VSTM
Verastem’s TARGET-D 202 Trial Puts Fresh Focus on KRAS G12D Lung Cancer
PremiumCompany Announcements
Verastem’s TARGET-D 202 Trial Puts Fresh Focus on KRAS G12D Lung Cancer
26d ago
VSTM
Verastem doses first patients in Target-D 203 Phase 2 trial
PremiumThe Fly
Verastem doses first patients in Target-D 203 Phase 2 trial
28d ago
VSTM
Verastem doses first patient in TARGET-D 202 Phase 2 trial
PremiumThe Fly
Verastem doses first patient in TARGET-D 202 Phase 2 trial
1M ago
VSTM
Verastem’s KRAS G12D Trial Targets a New Niche in Colorectal Cancer
PremiumCompany Announcements
Verastem’s KRAS G12D Trial Targets a New Niche in Colorectal Cancer
1M ago
VSTM
Citizens healthcare analysts hold an analyst/industry conference call
PremiumThe FlyCitizens healthcare analysts hold an analyst/industry conference call
2M ago
CTMX
EXEL
Verastem price target lowered to $14 from $15 at RBC Capital
Premium
The Fly
Verastem price target lowered to $14 from $15 at RBC Capital
2M ago
VSTM
Verastem’s RAMP 204 Trial Completion Signals New Momentum in KRAS G12C Lung Cancer
Premium
Company Announcements
Verastem’s RAMP 204 Trial Completion Signals New Momentum in KRAS G12C Lung Cancer
2M ago
VSTM
Cardiff, Verastem, Fluence, Quantum-Si, Opera Insider Shock
PremiumWeekend Updates
Cardiff, Verastem, Fluence, Quantum-Si, Opera Insider Shock
2M ago
QSI
CRDF
Verastem Advances VS-7375 with Promising Early Trial Data
PremiumCompany Announcements
Verastem Advances VS-7375 with Promising Early Trial Data
2M ago
8K
VSTM
Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial
PremiumThe Fly
Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial
2M ago
VSTM
Verastem price target lowered to $8 from $15 at Jefferies
PremiumThe Fly
Verastem price target lowered to $8 from $15 at Jefferies
2M ago
VSTM
Verastem’s KRAS G12D Pancreatic Cancer Trial Advances: What Investors Should Watch
PremiumCompany AnnouncementsVerastem’s KRAS G12D Pancreatic Cancer Trial Advances: What Investors Should Watch
2M ago
VSTM
Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial
Premium
Company Announcements
Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial
2M ago
8K
VSTM
Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study
Premium
The Fly
Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study
2M ago
VSTM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >